Get the Stockscreener App
193.93
0.95%
-2.0144
Icon Plc stock is traded at $193.93, with a volume of 222.36K.
It is down -0.95% in the last 24 hours and down -12.81% over the past month.
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
See More
Previous Close:
$195.94
Open:
$196.87
24h Volume:
222.36K
Relative Volume:
0.20
Market Cap:
$16.18B
Revenue:
$8.31B
Net Income/Loss:
$747.89M
P/E Ratio:
21.62
EPS:
8.97
Net Cash Flow:
$1.23B
1W Performance:
-2.52%
1M Performance:
-12.81%
6M Performance:
-36.70%
1Y Performance:
-27.87%
1-Day Range:
$191.88
$197.82
1-Week Range:
$191.88
$203.26
52-Week Range:
$183.38
$347.72
Icon Plc Stock (ICLR) Company Profile
Compare ICLR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ICLR
Icon Plc
|
193.83 | 16.18B | 8.31B | 747.89M | 1.23B | 8.97 |
|
TMO
Thermo Fisher Scientific Inc
|
572.45 | 219.06B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
207.58 | 151.02B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
145.80 | 42.12B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IDXX
Idexx Laboratories Inc
|
459.04 | 37.71B | 3.84B | 866.24M | 792.60M | 10.37 |
|
IQV
Iqvia Holdings Inc
|
208.03 | 36.97B | 15.32B | 1.41B | 1.96B | 7.62 |
Icon Plc Stock (ICLR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-25 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-14-24 | Initiated | Redburn Atlantic | Neutral |
| Sep-18-24 | Initiated | Leerink Partners | Outperform |
| Jun-06-24 | Initiated | Goldman | Buy |
| Dec-15-23 | Initiated | Truist | Buy |
| Sep-13-23 | Initiated | TD Cowen | Outperform |
| Jan-17-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Jan-13-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-09-22 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-07-22 | Initiated | UBS | Buy |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| May-24-22 | Initiated | Guggenheim | Buy |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-12-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Sep-27-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jul-23-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-14-21 | Initiated | Citigroup | Neutral |
| Apr-13-21 | Resumed | BofA Securities | Neutral |
| Apr-01-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Mar-03-21 | Initiated | Barclays | Equal Weight |
| Mar-01-21 | Upgrade | UBS | Neutral → Buy |
| Feb-26-21 | Upgrade | Truist | Hold → Buy |
| Jul-24-20 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-20-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-26-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-02-20 | Initiated | Deutsche Bank | Hold |
| Jan-27-20 | Downgrade | SunTrust | Buy → Hold |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Sep-23-19 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Jul-26-19 | Upgrade | UBS | Sell → Neutral |
| Jan-25-19 | Upgrade | Mizuho | Neutral → Buy |
| Oct-26-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-09-18 | Initiated | UBS | Sell |
| Apr-03-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-15-18 | Reiterated | Mizuho | Neutral |
| Jan-19-18 | Initiated | Evercore ISI | Outperform |
| Oct-27-17 | Reiterated | Barclays | Equal Weight |
| Sep-11-17 | Initiated | BofA/Merrill | Buy |
| Jul-31-17 | Upgrade | SunTrust | Hold → Buy |
| Jul-27-17 | Reiterated | Mizuho | Neutral |
| Jun-29-17 | Upgrade | Jefferies | Hold → Buy |
View All
Icon Plc Stock (ICLR) Latest News
Precision neuropsychiatry spotlight: a BioCentury podcast - BioCentury
ICON discovers over £10,000 of energy savings following audit by Green Zone Surveys - The Energyst
ICON plc (ICLR): Revolutionizing Clinical Trials with AI Innovations - Yahoo Finance
ICON Portfolio of AI Tools Drives Clinical Trial Efficiencies - sharewise
ICON's Game-Changing AI Tools Promise to Revolutionize Drug Development Process - StockTitan
ICON plc Schedules Fourth Quarter and Full Year 2024 Earnings Conference Call - sharewise
ICON plc to Announce 2024 Financial Results in February 2025 - TipRanks
TD Cowen cuts ICON stock price target to $254, maintains Buy rating - MSN
Contract Clinical Research Organization Market Set to Witness Significant Growth by 2025-2032:ICON plc, - EIN News
Europe Pharmacovigilance and Drug Safety Software Market Forecast, Regional Share and Growth Opportunity Analysis to 2031 - GlobeNewswire Inc.
ICON Public (ICLR) Stock Price, News & Analysis - MarketBeat
Arkadios Wealth Advisors Lowers Stock Holdings in ICON Public Limited (NASDAQ:ICLR) - Defense World
Healthcare Contract Research Outsourcing Market Projected To Witness Substantial Growth, 2025-2032: ICON plc, - EIN News
eClinical Solutions Market Key Players AnalysisIcon Plc, - openPR
RBC Capital Initiates Coverage of ICON Public Limited (ICLR) with Outperform Recommendation - MSN
Icon (ICLR) 3-Year EPS without NRI Growth Rate : 8.70% (As of Sep. 2024) - GuruFocus.com
Icon PLC (ICLR) Beats Q1 Earnings and Revenue Estimates - MSN
Icon sees FY25 adjusted EPS $13.00-$15.00, consensus $14.93 - Yahoo Finance
ICON stock target cut, maintains buy rating on financial guidance - Investing.com
Icon PLC (ICLR) Stock Price Down 6.6% on Jan 14 - GuruFocus.com
Clinical Research Firm ICON Faces Headwinds From Top Customers And Biotech Recovery Uncertainty - Benzinga
ICON plc stock retains Overweight rating amid conservative growth forecasts - Investing.com India
ICON plc stock retains Overweight rating amid conservative growth forecasts By Investing.com - Investing.com Australia
ICON Issues Financial Guidance for Full Year 2025 - sharewise
ICON plc Announces 2025 Financial Guidance Amid Market Challenges - TipRanks
ICON stock sinks following subdued 2025 financial guidance - Investing.com India
Decentralized Clinical Trials Market Recent Growth: Market - openPR
ICON Public (NASDAQ:ICLR) Earns Outperform Rating from Analysts at Royal Bank of Canada - Defense World
ICON Survey: 97% Use Biomarkers in Neurodegenerative Trials, But Innovation Gaps Persist - StockTitan
ICON's SWOT analysis: CRO giant faces headwinds amid long-term growth potential - Investing.com India
ICON plc draws bullish views at RBC on attractive valuation - MSN
Icon PLC (ICLR) Stock Price Up 4.66% on Jan 7 - GuruFocus.com
ICON plc to Present at the 43rd Annual J.P. Morgan Healthcare Conference - BioSpace
ICON plc to Present at the J.P. Morgan Healthcare Conference - TipRanks
Why Icon Plc Shares Face Rocky Times Ahead - TipRanks
ICON Properties Plc (ICON.mw) Q42024 Interim Report - AfricanFinancials
ICON Clinches TIME Magazine's Top CRO Ranking, Dominates Industry Awards in 2024 - StockTitan
ICON appoints Barry Balfe as COO - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages ICON Public Limited Company (ICLR) Shareholders to Inquire about Securities Investigation - AccessWire
Bioanalytical Services Market Key Players AnalysisPPD, Inc., - openPR
ICON plc appoints Barry Balfe as new COO By Investing.com - Investing.com Australia
ICON plc Appoints Barry Balfe as Chief Operating Officer - TipRanks
ICON plc appoints Barry Balfe as new COO - Investing.com
ICON Appoints 20-Year Veteran Barry Balfe as Chief Operating Officer to Drive Strategic Growth - StockTitan
Truist cuts ICON price target to reflect company commentary - Investing.com
ICON's SWOT analysis: CRO giant navigates turbulent market - Investing.com
Icon Plc Stock (ICLR) Financials Data
Revenue
Net Income
Cash Flow
EPS
8.49%
3.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):